Adult aggressive natural killer cell leukemia

Area of Science:

• Hematology
• Oncology
• Pathology

Background:

• Aggressive natural killer cell leukemia (ANKL) is a rare hematologic malignancy.
• ANKL is characterized by a poor prognosis and rapid disease progression.

Purpose of the Study:

• To retrospectively analyze clinical and laboratory data of ANKL patients.
• To identify diagnostic markers and prognostic factors for ANKL.
• To evaluate treatment responses in ANKL.

Main Methods:

• Retrospective analysis of clinical and laboratory data from 20 ANKL patients.
• Morphological and immunophenotypic evaluation of bone marrow (BM) biopsies and aspirates.
• Immunohistochemistry and Epstein-Barr virus (EBV)-encoded RNA detection.
• Cytogenetic analysis and EBV-DNA testing.

Main Results:

• Prominent complications included fever, pneumonia, hepatosplenomegaly, and liver dysfunction.
• BM biopsies revealed marked neoplastic cell infiltration, positive for CD2, CD56, and EBV-encoded RNA.
• All patients had positive plasma EBV-DNA; 8/20 showed complex cytogenetic abnormalities.
• Median survival was 8 weeks; jaundice due to liver dysfunction was a risk factor for early death.
• Patients were largely chemotherapy-resistant, though 3 responded to gemcitabine.

Conclusions:

• ANKL is a highly aggressive leukemia with a rapid clinical course.
• BM biopsy with immunohistochemistry and EBV-encoded RNA detection is crucial for diagnosis.
• Comprehensive evaluation and supportive care are essential before chemotherapy for severe complications to improve survival.